HC Wainwright & Co. Reiterates Buy on Iterum Therapeutics, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Iterum Therapeutics (NASDAQ: ITRM) and maintained a $6 price target.
June 21, 2024 | 5:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Iterum Therapeutics (NASDAQ: ITRM) and maintained a $6 price target.
The reiteration of a Buy rating and the maintenance of a $6 price target by a reputable analyst can boost investor confidence and potentially drive short-term price appreciation for Iterum Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100